BioCentury
ARTICLE | Finance

Zai shores up

How Zai Lab plans to use new cash after opting not to list in Hong Kong

September 14, 2018 7:18 PM UTC

As Zai Lab Ltd. (NASDAQ:ZLAB) prepares for its first product launch, more clinical work and additional deals to fortify its pipeline, the company passed on the chance to list on Hong Kong’s new biotech chapter, opting instead to raise $150 million in a NASDAQ follow-on priced Sept. 5.

Despite recent changes by Hong Kong Exchanges and Clearing Ltd. (HKEX) that allow prerevenue biotechs to list, Zai chose to stick with a NASDAQ offering rather than seek a dual listing. “In Hong Kong, we have no firm plans [for a listing],” CFO Billy Cho told BioCentury. “The U.S. was always going to be our primary focus, and our No. 1 goal has always been to strengthen our profile on NASDAQ.”...

BCIQ Company Profiles

Zai Lab Ltd.